Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver.
about
Serial measurement of hepatic lipids during chemotherapy in patients with colorectal cancer: a 1 H MRS studyChemotherapy-induced splenic volume increase is independently associated with major complications after hepatic resection for metastatic colorectal cancerEffect of preoperative FOLFOX chemotherapy on CCL20/CCR6 expression in colorectal liver metastases.Peroxisome proliferator-activated receptor-α staining is associated with worse outcome in colorectal liver metastases.Update on the role of imaging in management of metastatic colorectal cancerNoninvasive diagnosis of chemotherapy induced liver injury by LiMAx test--two case reports and a review of the literature.Curative strategies for liver metastases from colorectal cancer: a reviewRegulation of liver regeneration by growth factors and cytokines.Possibility of sandwiched liver surgery with molecular targeting drugs, cetuximab and bevacizumab on colon cancer liver metastases: a case report.Chemotherapy-associated hepatopathy in korean colorectal cancer liver metastasis patients: oxaliplatin-based chemotherapy and sinusoidal injury.A synthetic biology-based device prevents liver injury in miceOptimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases.Effect of neoadjuvant chemotherapy in patients with resectable colorectal liver metastases.Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer.What the emergency radiologist needs to know about treatment-related complications from conventional chemotherapy and newer molecular targeted agents.Recommendations of a group of experts for the pathological assessment of tumour regression of liver metastases of colorectal cancer and damage of non-tumour liver tissue after neoadjuvant therapy.Histological features and severity of oxaliplatin-induced liver injury and clinical associations.Multi-institutional phase II study on the feasibility of liver resection following preoperative mFOLFOX6 therapy for resectable liver metastases from colorectal cancers.Kinetic Changes in Liver Parenchyma After Preoperative Chemotherapy for Patients with Colorectal Liver Metastases.Oxaliplatin but not irinotecan impairs posthepatectomy liver regeneration in a murine model.Outcome of patients with colorectal liver metastasis: analysis of 1,613 consecutive cases.Development of a safety biomarker signature to detect hepatic sinusoidal dilation associated with an anti-DLL4 biotherapeutic.Fractal Dimension of Tc-99m DTPA GSA Estimates Pathologic Liver Injury due to Chemotherapy in Liver Cancer Patients.Treatment outcomes regarding the addition of targeted agents in the therapeutic portfolio for stage II-III rectal cancer undergoing neoadjuvant chemoradiation.Phase II trial of neoadjuvant chemotherapy with S-1 and oxaliplatin plus bevacizumab for colorectal liver metastasis (N-SOG 05 trial).Safety of liver resection in the elderly: how important is age?Hepatectomy for Colorectal Cancer Liver Metastases in the Era of Modern Preoperative Chemotherapy: Evaluation of Postoperative Complications.Treatment of colorectal liver metastases
P2860
Q30563967-427DF378-D79C-4728-910A-A33A3DD42B58Q33419966-F7B1A120-8288-4124-A3FE-7B3BF7E4E08BQ35171584-87D7C313-36DD-411D-B01A-1D2CA3C0F787Q35180034-4DE894E3-3083-4339-9EDF-6F90646E5223Q35285305-E64307EB-8324-4480-B186-9ED5EB8C9803Q35491201-6AA1B2BB-D80E-420C-A158-B55058096F33Q35776233-05A7CE8C-FBCE-494A-8225-A668FD1CD9CFQ36039310-AC06045A-0361-4CCC-B24E-FC63A5413289Q36338494-59460759-EF79-4D11-85F0-D99E3F3E1DABQ36343394-D8B6ABF4-6E75-4E2A-B3A1-73F6F2B4669AQ37023678-D490CACA-7987-4EFA-BE9D-CC0DF84A54C4Q37374065-6CF8ACB5-C872-4968-BA6C-7D1DF540E8B3Q37500453-DDA1593A-76C1-4FB3-AE5D-2A8657B0B0B1Q37907117-B2D8924D-F5B1-4960-B260-13F20ED67CCCQ38016741-2CA850A4-B294-4733-BED4-4822C458AB3BQ38135754-E94AD8D5-CB2C-47D9-B275-9183F4490992Q38233782-57845C7E-6B8F-47ED-82A1-9B1181D233BEQ38386343-BDFEF3A2-BA9D-41EB-95E5-0262367472C8Q39022926-9DBA6090-72A4-4903-BC8A-8D55F3153AC6Q39582592-EAC1B206-6185-491F-9043-6023CCF45BCBQ43413801-D190AD67-0487-4E4D-8DE3-B629567FED03Q46892548-6D160D00-74DB-4D86-BBC9-0317A83D5C78Q47959764-31696BD0-F9E5-4C71-8DAD-FCB396D4B27BQ49381573-A52289ED-5821-41E1-8774-823FBB643137Q50211002-CC983494-3C7C-4E80-B8A2-E3E97FBF96AEQ51534475-41E36F6C-FF1C-4C5F-A1A6-72E760989CCAQ53020665-79AECDE8-1FB7-49EC-ACA7-C1E9C2FBDEABQ59267675-00DAF05A-28D1-4C76-9600-E6EC2843FDA3
P2860
Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hepatic toxicities associated ...... l adenocarcinoma to the liver.
@en
Hepatic toxicities associated ...... l adenocarcinoma to the liver.
@nl
type
label
Hepatic toxicities associated ...... l adenocarcinoma to the liver.
@en
Hepatic toxicities associated ...... l adenocarcinoma to the liver.
@nl
prefLabel
Hepatic toxicities associated ...... l adenocarcinoma to the liver.
@en
Hepatic toxicities associated ...... l adenocarcinoma to the liver.
@nl
P2093
P1433
P1476
Hepatic toxicities associated ...... l adenocarcinoma to the liver.
@en
P2093
Andrew X Zhu
Gregory Y Lauwers
James M Cleary
Kenneth T Tanabe
P304
P356
10.1634/THEONCOLOGIST.2009-0152
P577
2009-10-30T00:00:00Z